Aptinyx (APTX) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
May 12, 2022 4:05 PM EDTCurrent cash position of > $100 million expected to fund operations into 2024 and enable readouts from all three ongoing Phase 2 studies
Data readout from Phase 2b study of NYX-2925 in fibromyalgia expected in early to mid 3Q 2022
Data readout from exploratory Phase 2 study of NYX-458 in cognitive impairment expected in late 2022 or 1Q 2023
Data readout from Phase 2b study of NYX-783 50 mg in PTSD expected in 2H 2023
Conference call today at 5:00 p.m. ET
EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq:... More
